Eli Lilly Offers New Safety, Efficacy Data From Phase 2 Study Evaluating Mirikizumab In Patients With Moderate To Severe Ulcerative Colitis: Showed Achivement Of Greater Rates Of Clinical Remission At 12 Weeks vs Placebo